Literature DB >> 4893253

Treatment of moderately severe erythema nodosum leprosum with thalidomide--a double-blind controlled trial.

J M Pearson, M Vedagiri.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1969        PMID： 4893253     DOI： 10.5935/0305-7518.19690022

Source DB:  PubMed          Journal:  Lepr Rev        ISSN： 0305-7518            Impact factor:   0.537


× No keyword cloud information.
  5 in total

Review 1.  Thalidomide in human immunodeficiency virus (HIV) patients. A review of safety considerations.

Authors:  V Günzler
Journal:  Drug Saf       Date:  1992 Mar-Apr       Impact factor: 5.606

2.  Thalidomide attenuates nitric oxide-driven angiogenesis by interacting with soluble guanylyl cyclase.

Authors:  Syamantak Majumder; Megha Rajaram; Ajit Muley; Himabindu S Reddy; K P Tamilarasan; Gopi Krishna Kolluru; Swaraj Sinha; Jamila H Siamwala; Ravi Gupta; R Ilavarasan; S Venkataraman; K C Sivakumar; Sharmila Anishetty; Pradeep G Kumar; Suvro Chatterjee
Journal:  Br J Pharmacol       Date:  2009-12       Impact factor: 8.739

Review 3.  Cancer therapies based on targeted protein degradation - lessons learned with lenalidomide.

Authors:  Max Jan; Adam S Sperling; Benjamin L Ebert
Journal:  Nat Rev Clin Oncol       Date:  2021-03-02       Impact factor: 66.675

Review 4.  Thalidomide: an antineoplastic agent.

Authors:  Robert J Amato
Journal:  Curr Oncol Rep       Date:  2002-01       Impact factor: 5.945

5.  A phase I trial of the HIV protease inhibitor nelfinavir in adults with solid tumors.

Authors:  Gideon M Blumenthal; Joell J Gills; Marc S Ballas; Wendy B Bernstein; Takefumi Komiya; Roopa Dechowdhury; Betsy Morrow; Hyejeong Root; Guinevere Chun; Cynthia Helsabeck; Seth M Steinberg; Jaclyn LoPiccolo; Shigeru Kawabata; Erin R Gardner; William D Figg; Phillip A Dennis
Journal:  Oncotarget       Date:  2014-09-30
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.